The new user fees are double the previous amount of $287 million. In exchange for the fees, the FDA has agreed to overall performance goals such as reviewing a certain percentage of applications within a specified time frame and hiring more than 200 full-time workers by the end of the five-year program. Details of the agreement, such as the fee structure, should be finalized soon.
Related Articles on Medical Devices:
Congress to Consider Bill to Repeal Medical Device Tax
FDA Announces 2012 Medical Device Strategic Priorities
FDA Misses Deadline in Conflict with Medical Device Makers Over Approval Process
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.